Tag: irinotecan

1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) and a MEK inhibitor (binimetinib) led to longer overall disease survival in patients with BRAF V600E mutated metastatic colorectal cancer as compared to control groups who received a single...
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) and a MEK inhibitor (binimetinib) led to longer overall disease survival in patients with BRAF V600E mutated metastatic colorectal cancer as compared to control groups who received a single...
Image: PD 1.  There is no significant difference in treating advanced gastric cancer refractory to chemotherapy with Paclitaxel or Irinotecan. Evidence rating level: 1 (Excellent)  Study Rundown: Gastric cancer, though uncommon in the United States, is among the most common cancers diagnosed worldwide. Though the development of chemotherapy with fluoropyrimidine plus platinum has...